| Abstrakt: |
Dengue is an important mosquito-borne human viral disease globally. Dynamic clinical presentations in affected subjects have been well documented. Majority of affected people are asymptomatic, and to some extent, mild dengue fever. Only small percentage of individuals progress to life-threatening dengue, dengue hemorrhagic fever, and dengue-shock syndrome, featured with increase vascular permeability and plasma leakage. Although the death rate is low, the consequence of the public burden is always underestimated. Currently, mosquito control and supportive care are the most common practice for dengue measure and patient care, respectively. Severe form of dengue is a time-dependent febrile illness since hemorrhagic or shock manifested at the time of defervescence period, and the virus has been cleared off from the circulation of affected hosts. Severe dengue is therefore considered to be a consequence of imbalance of host response to the infection. Therapeutic modalities that can inhibit or mitigate the progression of the disease have been investigated for many decades. However, these intensive efforts on the antiviral drugs to counter the dengue virus (DENV) infection as well as recent clinical trials with repurposing drugs or with natural products from herbal plants to prevent the plasma leakage have not yet produced exciting and effective outcomes. Knowledge gained during recent years demonstrates that the DENV may have a much more complicated life cycle than researchers initially thought of. Furthermore, traditionally, dengue has been viewed to be an acute febrile illness, but recent evidence suggests that asymptomatic DENV infections in healthy subjects are a likely event. This rekindles new avenue of developing therapeutic antiviral drugs to treat dengue. However, in order to advance our view on developing antiviral drugs to dengue, an unconventional wisdom deviated from classical textbook knowledge is an innovative step to build and guide through the process. |
Full text from SpringerLink